Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
enzyme replacement therapy |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
A16AB18
|
| gptkbp:brand |
gptkb:Mepsevii
|
| gptkbp:developer |
gptkb:Ultragenyx_Pharmaceutical
|
| https://www.w3.org/2000/01/rdf-schema#label |
vestronidase alfa
|
| gptkbp:indication |
treatment of Sly syndrome
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
recombinant human beta-glucuronidase
|
| gptkbp:mechanismOfAction |
replaces deficient beta-glucuronidase
|
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
anaphylaxis
rash urticaria infusion-related reactions |
| gptkbp:usedFor |
gptkb:mucopolysaccharidosis_VII
|
| gptkbp:bfsParent |
gptkb:Mepsevii
|
| gptkbp:bfsLayer |
8
|